Stoke Therapeutics (NASDAQ:STOK) Stock Price Expected to Rise, BTIG Research Analyst Says

Stoke Therapeutics (NASDAQ:STOK) had its target price hoisted by equities research analysts at BTIG Research from $28.00 to $39.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 11.62% from the stock’s current price.

Several other analysts have also weighed in on STOK. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Stoke Therapeutics in a report on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Needham & Company LLC raised their price objective on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Wedbush raised their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. Finally, Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They set a “buy” rating and a $30.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.83.

Stoke Therapeutics Stock Up 15.2%

Shares of STOK opened at $34.94 on Monday. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 41.11 and a beta of 1.24. The company has a 50-day moving average price of $21.76 and a two-hundred day moving average price of $14.22. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $35.08.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. The company had revenue of $13.82 million during the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. Equities research analysts expect that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total value of $250,700.00. Following the completion of the sale, the general counsel owned 11,831 shares of the company’s stock, valued at $296,603.17. This trade represents a 45.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Barry Ticho sold 5,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the sale, the insider directly owned 18,469 shares of the company’s stock, valued at approximately $366,979.03. This represents a 22.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 185,180 shares of company stock valued at $4,129,406 over the last quarter. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Siren L.L.C. grew its holdings in Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after acquiring an additional 247,347 shares during the period. GAMMA Investing LLC grew its holdings in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after acquiring an additional 5,084 shares during the period. Invesco Ltd. grew its holdings in Stoke Therapeutics by 117.0% during the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after acquiring an additional 14,118 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Stoke Therapeutics during the 1st quarter worth $2,376,000. Finally, Nuveen LLC acquired a new stake in Stoke Therapeutics during the 1st quarter worth $719,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.